| IDO1 高表达与肺鳞癌临床分期及不良预后相关 |
| |
| 引用本文： | 赵肖灵,郭军,雷秋香,刘丹丹,张树森,廖勇,刘登湘.IDO1 高表达与肺鳞癌临床分期及不良预后相关[J].医学分子生物学杂志,2023,20(1):40-44. |
| |
| 作者姓名： | 赵肖灵 郭军 雷秋香 刘丹丹 张树森 廖勇 刘登湘 |
| |
| 作者单位： | 河北医科大学附属医院邢台市人民医院;1. 肿瘤实验室,;2. 检验科, ;3.呼吸内科, ;4.肝胆外科 河北省邢台市,
054001 |
| |
| 基金项目： | 河北省自然科学基金青年科学基金项目 (No. H2021108003), 河北省 “三三三人才” 项目 (No. A202002032) |
| |
| 摘 要： | 目的 探讨不同分期肺鳞癌组织中 IDO1 的表达情况及与预后的关系。 方法 纳入河北医科大学
附属医院邢台市人民医院胸外科自 2017 年 1 月至 2019 年 1 月开展手术根治的肺鳞癌患者, 留取患者术中
癌组织标本, 用免疫组织化学染色法检测 IDO1 的表达情况, 并对患者进行术后随访。 结果 肺鳞癌组织
中有 IDO1 蛋白表达, 且临床Ⅱ ~ Ⅲ期阳性细胞数显著高于Ⅰ期。 截止随访结束时, 30 例患者中 28 例存
活, 2 例死亡, 疾病稳定 22 例 (73. 3 % ), 疾病进展 8 例 (26. 7 % )。 IDO1 高表达组和低表达组的无进展
生存期 (PFS) 分别为 26 个月和 40 个月, 差异具有统计学意义 (P< 0. 05); 高临床分期和低临床分期 PFS
分别为 33 个月和 40 个月, 差异具有统计学意义 (P< 0. 05)。 结论 IDO1 在肺鳞癌中表达量与临床分期有
关, 临床分期越高表达量越高, 患者预后也越差; IDO1 能指导临床分期和预后。
|
| 关 键 词： | 肺鳞癌 吲哚胺 2 3-双加氧酶 1 临床分期 无进展生存期 |
Correlation between IDO1 Expression and the Clinical Stage and Poor
Prognosis in Lung Squamous Cell Carcinoma |
| |
| ZHAO Xiaoling,GUO Jun,LEI Qiuxiang,LIU Dandan,ZHANG Shusen,LIAO Yong,LIU Dengxiang.Correlation between IDO1 Expression and the Clinical Stage and Poor
Prognosis in Lung Squamous Cell Carcinoma[J].Journal of Medical Molecular Biology,2023,20(1):40-44. |
| |
| Authors: | ZHAO Xiaoling GUO Jun LEI Qiuxiang LIU Dandan ZHANG Shusen LIAO Yong LIU Dengxiang |
| |
| Affiliation: | 1 Laboratory of Cancer Prevention and Treatment, 2Clinical Laboratory, 3Respiratory Medicine, 4Hepatobiliary Surgery, Xingtai People’s Hospital Affiliated to Hebei Medical University, Xingtai, Hebei,
054001, China |
| |
| Abstract: | Objective To investigate the expression of IDO1 in different stages of lung squamous cell carcinoma and its relationship with prognosis. Methods Patients with lung squamous cell
carcinoma who underwent radical surgery in the Department of thoracic surgery of Xingtai People’s
Hospital Affiliated to Hebei Medical University from January 2017 to January 2019 were included. Intraoperative cancer tissue samples were taken. The expression level of IDO1 was detected by
immunohistochemical staining, and the patients were followed up after operation. Results IDO1
protein was expressed in lung squamous cell carcinoma, and the number of positive cells in clinical
stages Ⅱ ~ Ⅲ was significantly higher than that in stage I. By the end of the follow-up, 28 of the
30 patients had survived, 2 died, 22 had stable disease (73. 3 % ), and 8 had disease progression (26. 7 % ). The progression free survival (PFS) ofido1high expression group andido1low expression group were 26 months and 40 months respectively (P < 0. 05). The PFS of higher clinical
stage and lower clinical stage were 33 months and 40 months respectively (P < 0. 05). Conclusion The expression level of IDO1 in lung squamous cell carcinoma was related to the clinical
stage. The higher the clinical stage, the higher the expression level, and the worse the prognosis of
patients. IDO1 expression level can be used to guide the clinical staging and prognosis in lung squamous cell carcinoma. |
| |
| Keywords: | lung squamous cell carcinoma indoleamine-2 3-dioxygenase 1 clinical stage PFS |
|
| 点击此处可从《医学分子生物学杂志》浏览原始摘要信息 |
|
点击此处可从《医学分子生物学杂志》下载全文 |
|
